Microgynon

Ethinylestradiol, the active ingredient in Microgynon, is a combined estrogen‑progestogen oral contraceptive presented as a 30 µg ethinylestradiol / 150 µg levonorgestrel oral tablet for oral use. It prevents pregnancy and provides hormonal contraception for women of reproductive age.

GNH USA supplies Microgynon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgynon, a combined estrogen‑progestogen oral contraceptive, is used within the hormonal contraception pathway to prevent pregnancy.

Prevention of pregnancy: provides reliable contraception by suppressing ovulation and altering cervical mucus. Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces menstrual flow. Management of dysmenorrhea: can lessen menstrual pain through hormonal stabilization.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Breast tenderness: swelling or discomfort of the breasts. - Headache: occasional tension‑type headache. - Spotting between periods: light vaginal bleeding.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins, requiring immediate medical attention. - Pulmonary embolism: clot migration to the lungs, a life‑threatening emergency. - Severe allergic reaction: hives, swelling, or anaphylaxis requiring urgent care.

Before prescribing Microgynon, clinicians should consider the following precautions: - Assess cardiovascular risk: avoid in women with a history of thromboembolic disorders. - Screen for smoking status: contraindicated in smokers over 35 years of age. - Evaluate liver function: use with caution in hepatic impairment. - Consider drug interactions: avoid concomitant use with enzyme‑inducing medicines that may reduce efficacy. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Microgynon may interact with several medicines that affect hormone metabolism.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce contraceptive effectiveness. - Rifampicin: significantly lowers hormone levels, increasing risk of unintended pregnancy. - Protease inhibitors (e.g., ritonavir): can alter hormone metabolism and compromise efficacy.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., ampicillin, tetracycline): may slightly reduce efficacy; monitor menstrual cycle. - St. John’s wort: may decrease hormone concentrations; advise caution. - Diuretics (e.g., spironolactone): may increase risk of hypertension; monitor blood pressure.